DEMO manufactures generic injectables for hospital and public-health markets, exporting 80% of annual output. The tech stack reveals a manufacturing-focused operation—heavy on SAP (core ERP), analytical instrumentation (HPLC, LC-MS, GC/MS, qPCR), and industrial automation (Siemens PLC, SCADA, PROFINET)—with active migration to SAP S/4HANA. Hiring velocity is accelerating across research, engineering, and manufacturing roles, driven by a €356-million investment in production capacity and biotech R&D; concurrent projects in biosimilars development, validation master plans, and contamination-control strategy point to facility expansion and regulatory complexity.
DEMO is Greece's largest manufacturer of injectable pharmaceuticals, with over 1,400 employees across a major facility in Southeast Europe. The company supplies public hospitals in Greece as a primary domestic channel while exporting to 86 countries; it holds official supplier status with the UN, UNICEF, WHO, and humanitarian organizations. The product portfolio spans generic injectables, contract manufacturing, and an emerging biosimilars pipeline. Current capital deployment (€356 million) targets expanded manufacturing capacity, R&D infrastructure, and a transition into active pharmaceutical ingredient (API) and biotechnology production.
Injectable pharmaceuticals for hospitals and public-health systems, generic active ingredients, and contract manufacturing. The company is Greece's largest injectable supplier and exports to 86 countries. Biosimilars development is underway as part of a biotech-expansion roadmap.
SAP and SAP S/4HANA are the core enterprise systems. The company is actively migrating to S/4HANA as part of its broader ERP modernization journey.
Other companies in the same industry, closest in size